Cipla Ltd (IN:CIPLA)
:CIPLA
Top Page
Cipla Ltd
(CIPLA)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹1,340.00
▼(-11.80% Downside)
Action:DowngradedDate:11/01/25
Cipla Ltd's overall stock score is driven primarily by its strong financial performance, which highlights growth potential and financial resilience. However, technical indicators suggest a bearish trend, which tempers the overall score. The valuation is fair, providing a balanced view of the stock's potential.
Positive Factors
Low leverage & strong equity base
Cipla's extremely low leverage and high equity ratio provide durable financial flexibility to fund R&D, capex, or M&A without stressing cash flows. A strong equity base and 16.9% ROE support resilience through generic pricing cycles and allow long-term strategic investments.
Negative Factors
Negative EPS growth
A decline in EPS despite margin improvements raises questions about per-share earnings quality or one-off impacts (e.g., non-operating items or share base changes). Persistent negative EPS growth would undermine shareholder returns and signal volatility in reported profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage & strong equity base
Cipla's extremely low leverage and high equity ratio provide durable financial flexibility to fund R&D, capex, or M&A without stressing cash flows. A strong equity base and 16.9% ROE support resilience through generic pricing cycles and allow long-term strategic investments.
Read all positive factors
Cipla Ltd (CIPLA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹993.25B
Dividend Yield0.87%
Average Volume (3M)41.77K
Price to Earnings (P/E)45.1
Beta (1Y)0.75
Revenue Growth6.93%
EPS Growth21.55%
CountryIN
Employees27,764
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)8.36
Shares Outstanding807,782,650
10 Day Avg. Volume63,362
30 Day Avg. Volume41,773
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)3.74
Price to Sales (P/S)4.28
P/FCF Ratio30.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)54.83
Revenue Forecast (FY)₹307.90B
Cipla Ltd Business Overview & Revenue Model
Company Description
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therape...
How the Company Makes Money
Cipla primarily makes money by selling pharmaceutical products to healthcare channels (including wholesalers/distributors, pharmacies, hospitals, and government/institutional buyers) in India and in overseas markets. Its core revenue stream is the...
Cipla Ltd Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 282.28B | 272.67B | 255.37B | 225.59B | 217.08B | 191.21B |
| Gross Profit | 156.84B | 180.92B | 164.93B | 141.04B | 130.18B | 116.14B |
| EBITDA | 76.80B | 70.22B | 61.91B | 49.19B | 44.39B | 41.24B |
| Net Income | 54.41B | 52.73B | 41.22B | 28.02B | 25.17B | 24.05B |
Balance Sheet | ||||||
| Total Assets | 401.64B | 373.87B | 327.18B | 294.63B | 271.01B | 251.52B |
| Cash, Cash Equivalents and Short-Term Investments | 83.35B | 106.17B | 77.96B | 62.77B | 46.32B | 37.46B |
| Total Debt | 4.67B | 4.39B | 5.60B | 8.03B | 10.56B | 20.24B |
| Total Liabilities | 71.39B | 60.98B | 59.15B | 57.50B | 59.84B | 65.66B |
| Stockholders Equity | 329.19B | 311.93B | 267.07B | 234.08B | 208.42B | 183.27B |
Cash Flow | ||||||
| Free Cash Flow | 6.80B | 38.43B | 27.85B | 20.55B | 26.25B | 29.36B |
| Operating Cash Flow | 13.45B | 50.05B | 41.34B | 32.38B | 33.26B | 37.55B |
| Investing Cash Flow | 1.59B | -36.91B | -29.88B | -23.89B | -18.72B | -23.87B |
| Financing Cash Flow | -13.18B | -12.93B | -12.00B | -9.58B | -16.00B | -12.40B |
Cipla Ltd Technical Analysis
Negative
1519.30
Price Trends
1298.45
Negative
1393.41
Negative
1462.93
Negative
Market Momentum
-29.69
Negative
40.64
Neutral
66.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CIPLA, the sentiment is Negative. The current price of 1519.3 is above the 20-day moving average (MA) of 1246.31, above the 50-day MA of 1298.45, and above the 200-day MA of 1462.93, indicating a bearish trend. The MACD of -29.69 indicates Negative momentum. The RSI at 40.64 is Neutral, neither overbought nor oversold. The STOCH value of 66.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CIPLA.
Cipla Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹80.45B | 38.14 | ― | 4.73% | -19.94% | -22.49% | |
69 Neutral | ₹222.58B | 40.22 | ― | 0.69% | 6.13% | 35.83% | |
68 Neutral | ₹993.25B | 45.14 | ― | 0.87% | 6.93% | 21.55% | |
67 Neutral | ₹547.60B | 41.01 | ― | 1.68% | 10.69% | 17.46% | |
63 Neutral | ₹405.43B | 35.44 | ― | 2.16% | 4.17% | 41.51% | |
61 Neutral | ₹286.65B | 27.13 | ― | 1.07% | -1.51% | 14.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:CIPLA
Cipla Ltd
1,229.60
-236.13
-16.11%
IN:ABBOTINDIA
Abbott India Limited
25,770.05
-4,804.11
-15.71%
IN:GLAND
Gland Pharma Ltd.
1,739.85
326.42
23.09%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,393.25
-446.44
-15.72%
IN:PFIZER
PFIZER LIMITED
4,865.30
791.61
19.43%
IN:SANOFI
Sanofi India Limited
3,493.20
-2,494.68
-41.66%
Cipla Ltd Corporate Events
Cipla shareholders clear appointment of Achin Gupta as MD and Global CEO via postal ballot
Mar 26, 2026
Cipla Limited has announced that shareholders have approved, via postal ballot, key board and management changes, including the appointment of Achin Gupta as director, managing director and global chief executive officer, and the re-appointment of...
Cipla Issues 1,954 Shares Under Employee Stock Schemes
Mar 18, 2026
Cipla Limited has allotted 1,954 fully paid-up equity shares of INR 2 each following the exercise of employee stock options and stock appreciation rights under its ESOS 2013-A and Cipla ESAR Scheme 2021. As a result of this relatively small issuan...
Cipla USA Recalls Lanreotide Injection, Causing Temporary Supply Disruption
Mar 9, 2026
Cipla’s U.S. subsidiary, Cipla USA Inc., has decided to initiate a recall of unexpired batches of Lanreotide Injection following discussions with Pharmathen International S.A. The move will result in a temporary lack of supply of this produc...
Cipla Seeks Shareholder Nod for New Global CEO and Board Changes via Postal Ballot
Feb 23, 2026
Cipla has initiated a postal ballot process to seek shareholder approval for key board and management changes, including the appointment of Achin Gupta as a director, and as managing director and global chief executive officer, along with approval...
Cipla Says Maharashtra GST Inspection Concludes With No Material Impact
Feb 8, 2026
Cipla Limited has disclosed that an inspection and search conducted by the Maharashtra Goods Service Tax Department under Section 67 of the Maharashtra GST Act, 2017, has been concluded as of 7 February 2026. The company stated it has provided al...
Cipla Appoints Arun Kakatkar as Global Chief People Officer
Feb 2, 2026
Cipla Ltd has announced a key change in its senior management, with the Board approving the appointment of Arun Kakatkar as Global Chief People Officer and Senior Management Personnel, effective 17 March 2026. Kakatkar, an experienced business lea...
Cipla Publishes Q3 FY26 Earnings Call Transcript for Investors
Jan 27, 2026
Cipla Limited has released the transcript of its Q3 FY26 earnings conference call, held on 23 January 2026, and made it available to investors and the public via its website and stock exchanges. The disclosure, led by Managing Director and Global ...
Cipla Publishes Audio Recording of Q3 and Nine-Month FY2025 Earnings Call
Jan 23, 2026
Cipla Limited has notified stock exchanges in India and the Luxembourg Stock Exchange that the audio recording of its earnings conference call for the quarter and nine months ended 31 December 2025 has been made available on the company’s we...
Cipla Warns of Temporary Lanreotide Supply Disruption After USFDA Observations at Supplier
Jan 14, 2026
Cipla has disclosed that its key U.S. product Lanreotide Injection faces a temporary supply disruption after the USFDA issued nine inspectional observations for its exclusive supplier, Pharmathen International S.A., following an inspection of Phar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.